News

TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop

On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development.

The presentations from the 4th International Workshop on Clin. Pharm. of TB Drugs are available [click here].

Key abstracts from ICAAC were:

Authors Abstract Title
  • Diacon, R. Dawson, C. Van Niekerk, N. Erondu, A. Ginsberg

Pyrazinamide Increases the Early Bactericidal Activity of TMC207 and PA-824 in Patients with Newly Diagnosed, Smear-positive Pulmonary Tuberculosis
  • A. Diacon, R. Dawson, C. Van Niekerk, N. Erondu, A. Ginsberg
Phase 2 Trial of a Novel 3-Drug Regimen for Both MDR and Drug Sensitive (DS) TB
  • R. Tasneen, S. Li, K. Andries, K. Mdluli, E. Nuermberger
Novel TMC207-containing Regimens Have Sterilizing Activity In Murine Tuberculosis
  • H. Huang , K. Liu, D. Zhang, B. Liu, G. Zhang, H. Zhang, Y. Li, Master C. Zhang, Y. Liu, J. Wang, Y. Lu, M. Zheng, B. Wang, T. Yang, X. Li, C. Li, C. B. Cooper, Z. Ma, D. Yin
SAR of Riminophenazine Class and Discovery of New Anti-tuberculosis Agents Active Against Multidrug-Resistant Tuberculosis
  • Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu, H. Jin, D. Yin, H. Huang, Z. Ma

Clofazimine Analogs with Superior Efficacy against Experimental Tuberculosis and Reduced Potential

for Tissue Discoloration

  • M. Upton, A. Shadiack, Z. Ma, Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu,
  • H. Jin, D. Yin, H. Huang
Anti-tubercular Clofazimine Analogs that Demonstrate a Range of Tissue Distribution Patterns Following Eight Weeks Dosing to Mice
  • K. C. Chang, W. W. Yew, S. W. Cheung, C. C. Leung
Extensively Drug-resistant Tuberculosis (XDR-TB) Treated with Daily/ Intermittent Linezolid
  • L. Manzini, M. Parracino, D. Iemmi, G. Lapadula, A. Gori, E. Girardi, C. Mussini
Tolerability of Moxifloxacin as Part of Anti-Tuberculous Treatment

Additional TB R&D News:

Epistem successfully completes first-round testing of TB diagnostic device

Lilly Launches Open Innovation Drug Discovery Platform to Help Find Potential New Medicines Where Medical Need is Great

Open Innovation Drug Discovery [Actual Website]

Drug-Evading Tuberculosis Shows Rising Superbug Threat in China


More News
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...